Speaking on national television late Wednesday night Gitahi said the rumours that the brand availed to Kenya by COVAX-supplied had been rejected elsewhere should be eschewed as the Covid-19 variant to which the vaccine was not effective in South Africa is not the same prevalent in Kenya.
People allergic to egg proteins or chicken allergy are safe with the vaccine as it has no components of such proteins in its make-up. The area concerning pregnant women is still grey and research furiously ongoing. However Frontline workers in whatever state they are would find it more prudent to get the vaccine than opt out for fear of side-effects.
Dr. Gitahi also revealed that the vaccine does not stop one from being infected, it only stops one from showing severe symptoms of the disease.
Speaking on the same show Dr Eunice Ndirangu said the vaccines are here and we should stop absorbing misinformation in the social media and take up the chance to redeem ourselves.
Content created and supplied by: Dalanews (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More